Efficacy and Safety of Levofloxacin Combined with Ambroxol in the Treatment of Patients with Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Infection
Objective To investigate the efficacy and safety of levofloxacin combined with ambroxol in the treatment of patients with chronic obstructive pulmonary disease(COPD)complicated with pulmonary infection.Methods According to the random number table method,58 patients with COPD complicated with pulmonary infection admitted to Yihuang County Hospital of Traditional Chinese Medicine from January 2021 to September 2023 were divided into control group and study group,with 29 patients in each group.The control group was treated with levofloxacin,and the study group was treated with levofloxacin combined with ambroxol.The total effective rate of clinical treatment,inflammatory factor level,blood gas index level,lung function and incidence of adverse reactions were compared between the two groups.Results Compared with the total effective rate of clinical treatment in the control group(68.97%),the total effective rate of clinical treatment in the study group(96.44%)was higher(P<0.05).Compared with the control group,PCT,IL-6,TNF-α,PaCO2 were lower,SpO2,PaO2,MVV,FVC,FEV1,FEV1/FVC were higher in the study group after treatment(P<0.05).Compared with the incidence of adverse reactions in the control group(24.14%),the incidence of adverse reactions in the study group was lower(3.45%)(P<0.05).Conclusion The combination of levofloxacin and ambroxol can improve the clinical effect of COPD patients with pulmonary infection,reduce the level of airway inflammation and blood gas index,and improve the lung function of patients,which is safe and reliable.
LevofloxacinAmbroxolChronic obstructive pulmonary diseasePulmonary infectionLung function
国家科技期刊平台
NSTL
万方数据
